Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 3 boards, counting each seat separately. Longest: Zoetis Inc., 3 years.
Zoetis Inc.
Director
Praxis Precision Medicines Inc.
Director
Royalty Pharma plc
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Praxis Precision Medicines Inc. June 10, 202698.8%
-
Royalty Pharma plc June 4, 202698.8%
-
Zoetis Inc. May 20, 202692.2%
-
Zoetis Inc. May 21, 202593.3%
-
Royalty Pharma plc May 12, 202597.5%
-
Royalty Pharma plc June 6, 202497.3%
-
Zoetis Inc. May 21, 202495.7%
-
Royalty Pharma plc June 22, 202383.2%
-
Praxis Precision Medicines Inc. June 12, 202382.7%
-
Zoetis Inc. May 18, 202397.9%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 10, 2026 | Praxis Precision Medicines Inc. | Grant or award | +1,371 | — | — |
| Jun 5, 2026 | Royalty Pharma plc | Grant or award | +4,545 | — | — |
| May 14, 2026 | Royalty Pharma plc | Open-market sale | −3,045 | $53.00 | $161,385 |
| Mar 9, 2026 | Zoetis Inc. | Gift | −1,213 | — | — |
| Feb 19, 2026 | Zoetis Inc. | Option exercise | +1,619 | — | — |
| Feb 19, 2026 | Zoetis Inc. | Other | −406 | $127.28 | $51,676 |
| Aug 11, 2025 | Royalty Pharma plc | Open-market sale | −33,500 | $36.23 | $1,213,705 |
| Aug 8, 2025 | Royalty Pharma plc | Derivative conversion | +144,660 | — | — |
| May 13, 2025 | Royalty Pharma plc | Grant or award | +7,614 | — | — |
| Feb 14, 2025 | Zoetis Inc. | Gift | −1,843 | — | — |
| Feb 8, 2025 | Zoetis Inc. | Option exercise | +1,225 | — | — |
| Feb 8, 2025 | Zoetis Inc. | Other | −308 | $171.43 | $52,800 |
| Feb 6, 2025 | Zoetis Inc. | Option exercise | +1,236 | — | — |
| Feb 6, 2025 | Zoetis Inc. | Other | −310 | $174.12 | $53,977 |
| Jun 7, 2024 | Royalty Pharma plc | Grant or award | +9,293 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.